Market cap
$6,165 Mln
Recently Viewed
Clear All$99.99
$0.00 (0.00%)As on 14-Mar-2022 09:30EDT
Market cap
$6,165 Mln
Revenue (TTM)
$-3 Mln
P/E Ratio
--
P/B Ratio
9.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-616 Mln
ROE
-0.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
3.5
Debt to Equity
0.1
Book Value
$11
EPS
$-10.1
Face value
--
Shares outstanding
61,659,400
CFO
$-668.17 Mln
EBITDA
$-936.14 Mln
Net Profit
$-1,040.33 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arena Pharmaceuticals Inc (ARNA)
| 7.6 | 6.6 | 11.0 | 29.7 | 29.9 | 47.3 | 18.6 |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Arena Pharmaceuticals Inc (ARNA)
| 21.0 | 69.2 | 16.6 | 14.6 | 139.2 | -25.3 | -45.2 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arena Pharmaceuticals Inc (ARNA)
|
100.0 | 6,165.3 | 0.1 | -616.4 | 16,017.4 | -70.3 | -- | 9.2 |
| 4.0 | 375.2 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.0 | |
| 20.3 | 1,201.4 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 7.3 | |
| 13.4 | 2,297.2 | 550.0 | 458.1 | -3.3 | 45.9 | 5 | 1.9 | |
| 5.2 | 1,025.8 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 15.8 | 2,010.3 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.5 | |
| 16.7 | 1,155.1 | 403.3 | 22.8 | 3,081.6 | 9.1 | 408.9 | 4.2 | |
| 3.4 | 637.6 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.5 | |
| 18.9 | 423.6 | 4.8 | 53.5 | -- | 12.2 | 10.2 | 1.1 | |
| 21.5 | 2,331.3 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.3 |
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase... III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc. Read more
Pres & CEO
Mr. Amit D. Munshi M.B.A.
Pres & CEO
Mr. Amit D. Munshi M.B.A.
Headquarters
Park City, UT
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Arena Pharmaceuticals Inc (ARNA) is $99.99 (NASDAQ) as of 14-Mar-2022 09:30 EDT. Arena Pharmaceuticals Inc (ARNA) has given a return of 29.86% in the last 3 years.
Since, TTM earnings of Arena Pharmaceuticals Inc (ARNA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-9.20
|
8.42
|
|
2020
|
-10.44
|
3.91
|
|
2019
|
5.94
|
2.20
|
|
2018
|
-62.27
|
3.02
|
|
2017
|
-12.26
|
5.41
|
The 52-week high and low of Arena Pharmaceuticals Inc (ARNA) are Rs -- and Rs -- as of 01-May-2026.
Arena Pharmaceuticals Inc (ARNA) has a market capitalisation of $ 6,165 Mln as on 14-Mar-2022. As per SEBI classification, it is a company.
Before investing in Arena Pharmaceuticals Inc (ARNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.